PVLA

Palvella Therapeutics, Inc. Common Stock

PVLA

Market cap $629M

Overview Fund Activity

56.84 USD

-1.61

2.75%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

56.50

-0.34

0.6%

1 day

-2.75%

5 days

0.42%

1 month

31.54%

3 months

115.14%

6 months

96%

Year to date

373.67%

1 year

233.76%

5 years

-75.67%

10 years

-71.23%

About: Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Employees: 14

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,300% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 2

111% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 9

63% more funds holding

Funds holding: 41 [Q1] → 67 (+26) [Q2]

7.79% more ownership

Funds ownership: 45.66% [Q1] → 53.45% (+7.79%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

7% less capital invested

Capital invested by funds: $143M [Q1] → $133M (-$10.2M) [Q2]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$54

-5% downside

Avg. target

$69

22% upside

High target

$90

58% upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

Oppenheimer Trevor Allred	$85	Outperform Initiated	9 Sep 2025
Canaccord Genuity Whitney Ijem	$66	Buy Maintained	19 Aug 2025
HC Wainwright & Co. Andrew S. Fein	$75	Buy Maintained	15 Aug 2025
Chardan Capital Geulah Livshits	$60	Buy Maintained	15 Aug 2025
Raymond James Ryan Deschner	$54	Outperform Initiated	6 Aug 2025
LifeSci Capital Sam Slutsky	$90	Outperform Initiated	4 Aug 2025
Truist Securities Danielle Brill	$56	Buy Initiated	21 Jul 2025

See Analyst Rankings

Financial journalist opinion

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D.

Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D.

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

WAYNE, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will present at two upcoming healthcare investor conferences. The details are as follows:

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations completed enrollment, exceeding enrollment target by over 25%; top-line results on track for the first quarter of 2026

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its second quarter 2025 financial results on Thursday, August 14, 2025. Palvella management will host a conference call for investors at 8:30 a.m.

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

WAYNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 1:00 p.m. ET.

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc . (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced it has been added to the broad-market Russell 3000® Index and the Russell 2000® Index, effective after the U.S. market opens on June 30, as part of the 2025 Russell indexes reconstitution.

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

New intellectual property builds on Palvella's multi-layered exclusivity strategy Patent term expected through at least 2038 WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the United States Patent and Trademark Office (USPTO) issued patent No.

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

FDA Orphan Products Grants are awarded based on rigorous scientific and technical review by rare disease and regulatory experts

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

Ms. Kline to lead Palvella's commercial buildout for planned standalone U.S. launch of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations, a serious, rare, and lifelong genetic disease affecting an estimated more than 30,0000 patients in the U.S., if approved Under Kline's leadership at Dompé, Oxervate®, a first-in-disease topical therapy for rare disease neurotrophic keratitis, scaled to over $500 million in annual U.S. sales while achieving early profitability WAYNE, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the appointment of Ashley Kline as Chief Commercial Officer, effective immediately.

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

See News Rankings

Charts implemented using Lightweight Charts™